Mucin 1-mediated chemo-resistance in lung cancer cells

Oncogenesis

Volumn 5, Issue , 2016, Pages 1-8

  Ham, S Y ^a   Kwon, T ^a   Bak, Y ^a   Yu, J H ^b   Hong, J ^c   Lee, S K ^d   Yu, D Y ^e   Yoon, D Y ^a  

^a Konkuk University   (South Korea)

^b UNIVERSITY OF WISCONSIN   (United States)

^c Chungbuk National University   (South Korea)

^d Seoul National University   (South Korea)

^e Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85014491570     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2015.47     Document Type: Article

References (39)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10–29.
2. Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: diagnosis and management. Am Fam Physician 2007; 75: 56–63.
3. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet 2013; 382: 709–719.
4. Silva S, Danson S. Targeted therapy and new anticancer drugs in advanced disease. Thorac Surg Clin 2013; 23: 411–419.
5. Liu J, Meisner D, Kwong E, Wu XY, Johnston MR. Translymphatic chemotherapy by intrapleural placement of gelatin sponge containing biodegradable Paclitaxel colloids controls lymphatic metastasis in lung cancer. Cancer Res 2009; 69: 1174–1181.
6. Hoang T, Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol 2012; 7: 1361–1368.
7. Monzo M, Rosell R, Sanchez JJ, Lee JS, O'Brate A, Gonzalez-Larriba JL et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999; 17: 1786–1793.
8. Yin S, Zeng C, Hari M, Cabral F. Paclitaxel resistance by random mutagenesis of alpha-tubulin. Cytoskeleton 2013; 70: 849–862.
9. Zuo KQ, Zhang XP, Zou J, Li D, Lv ZW. Establishment of a paclitaxel resistant human breast cancer cell strain (MCF-7/Taxol) and intracellular paclitaxel binding protein analysis. J Int Med Res 2010; 38: 1428–1435.
10. Vinogradov S, Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond) 2012; 7: 597–615.
11. Jung MJ, Rho JK, Kim YM, Jung JE, Jin YB, Ko YG et al. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene 2013; 32: 209–221.
12. Spratlin J, Sawyer MB. Pharmacogenetics of paclitaxel metabolism. Crit Rev Oncol Hematol 2007; 61: 222–229.
13. Han X, Du F, Jiang L, Zhu Y, Chen Z, Liu Y et al. A2780 human ovarian cancer cells with acquired paclitaxel resistance display cancer stem cell properties. Oncol Lett 2013; 6: 1295–1298.
14. Vidal SJ, Rodriguez-Bravo V, Galsky M, Cordon-Cardo C, Domingo-Domenech J. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene 2014; 33: 4451–4463.
15. Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med 2014; 20: 332–342.
16. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009; 9: 874–885.
17. Kharbanda A, Rajabi H, Jin C, Tchaicha J, Kikuchi E, Wong KK et al. Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells. Clin Cancer Res 2014; 20: 5423–5434.
18. Li Y, Kuwahara H, Ren J, Wen G, Kufe D. The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. J Biol Chem 2001; 276: 6061–6064.
19. Li Y, Ren J, Yu W, Li Q, Kuwahara H, Yin L et al. The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J Biol Chem 2001; 276: 35239–35242.
20. Ahmad R, Raina D, Trivedi V, Ren J, Rajabi H, Kharbanda S et al. MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling. Nat Cell Biol 2007; 9: 1419–1427.
21. Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M et al. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther 2011; 10: 806–816.
22. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D. MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res 2005; 65: 10413–10422.
23. Kharbanda A, Rajabi H, Jin C, Alam M, Wong KK, Kufe D. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. Oncotarget 2014; 5: 8893–8905.
24. Kim EH, Min HY, Chung HJ, Song J, Park HJ, Kim S et al. Anti-proliferative activity and suppression of P-glycoprotein by (-)-antofine, a natural phenanthroindolizidine alkaloid, in paclitaxel-resistant human lung cancer cells. Food Chem Toxicol 2012; 50: 1060–1065.
25. Medici D, Hay ED, Olsen BR. Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3. Mol Biol Cell 2008; 19: 4875–4887.
26. Biddle A, Mackenzie IC. Cancer stem cells and EMT in carcinoma. Cancer Metastasis Rev 2012; 31: 285–293.
27. Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 2011; 8: 486–498.
28. Ucar D, Cogle CR, Zucali JR, Ostmark B, Scott EW, Zori R et al. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact 2009; 178: 48–55.
29. Ren J, Raina D, Chen W, Li G, Huang L, Kufe D. MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling. Mol Cancer Res 2006; 4: 873–883.
30. Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L et al. Human MUC1 carcinomaassociated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004; 5: 163–175.
31. Morrison BJ, Hastie ML, Grewal YS, Bruce ZC, Schmidt C, Reynolds BA et al. Proteomic comparison of mcf-7 tumoursphere and monolayer cultures. PLoS ONE 2012; 7: e52692.
32. Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY, Le XF et al. Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance. PLoS ONE 2014; 9: e113478.
33. Li G, Zhao L, Li W, Fan K, Qian W, Hou S et al. Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. Oncotarget 2014; 5: 8317–8329.
34. Situ D, Wang J, Ma Y, Zhu Z, Hu Y, Long H et al. Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer. Med Oncol 2011; 28: S596–S604.
35. Alam M, Rajabi H, Ahmad R, Jin C, Kufe D. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. Oncotarget 2014; 5: 2622–2634.
36. Alam M, Ahmad R, Rajabi H, Kharbanda A, Kufe D. MUC1-C oncoprotein activates ERK--4C/EBPbeta signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cells. J Biol Chem 2013; 288: 30892–30903.
37. Leng Y, Cao C, Ren J, Huang L, Chen D, Ito M et al. Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem 2007; 282: 19321–19330.
38. Tsai LL, Yu CC, Chang YC, Yu CH, Chou MY. Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. J Oral Pathol Med 2011; 40: 621–628.
39. Reza HM, Ng BY, Phan TT, Tan DT, Beuerman RW, Ang LP. Characterization of a novel umbilical cord lining cell with CD227 positivity and unique pattern of P63 expression and function. Stem Cell Rev 2011; 7: 624–638.